The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Antitumor activity of amivantamab by consensus molecular subtypes in RAS/BRAF wild-type metastatic colorectal cancer: Secondary analyses from the phase 1b/2 OrigAMI-1 study.
 
Marcia Cruz-Correa
Employment - Pan American Center for Oncology Trials
Stock and Other Ownership Interests - Pan American Center for Oncology Trials
Consulting or Advisory Role - BeOne Pharmaceutical
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb/Celgene (Inst); Genentech/Roche (Inst); GENFIT (Inst); HUYA Bioscience International (Inst); Incyte Japan (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); VMO (Inst)
 
Sae-Won Han
Stock and Other Ownership Interests - IMBdx
Consulting or Advisory Role - Abbvie; AstraZeneca; IMBdx; Natera
Research Funding - Abbvie (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BeyondBio (Inst); Boryung (Inst); Cell Biotech (Inst); GC Pharma (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Hanmi (Inst); Hengrui Pharmaceutical (Inst); IMBdx (Inst); Janssen (Inst); Jeil Pharmaceutical Co (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck KGaA (Inst); Mirati Therapeutics (Inst); MSD (Inst); Roche (Inst); Seagen (Inst)
 
Rozita Abdul Malik
Research Funding - AstraZeneca (Inst); Janssen Research & Development (Inst); Merck Sharp & Dohme (Malaysia) Sdn Bhd (Inst); Novartis (Inst); Roche (Malaysia) Sdn Bhd (Inst)
 
Harvey Yu-Li Su
Honoraria - Amgen; Bayer; Boehringer Ingelheim; Fresenius Kabi; Johnson & Johnson/Janssen; Merck KGaA; Novartis; Pfizer; Takeda
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Merck Serono; MSD Oncology
Speakers' Bureau - Merck KGaA; Pfizer
Travel, Accommodations, Expenses - Merck KGaA; Takeda
 
Marc Van den Eynde
Consulting or Advisory Role - AstraZeneca, Servier, Merck, GSK, Astellas, BMS, MSD, Nordic, BeOne, Amgen (Inst)
Research Funding - Janssen Global Services, LLC, a Johnson & Johnson Company
Travel, Accommodations, Expenses - Servier, Merck, Amgen, MSD, AstraZeneca (Inst)
Other Relationship - Participation on a data safety monitoring board or advisory board: AstraZeneca, Servier, Nordic, GSK, BMS, MSD, Merck (Inst)
 
Paul Oberstein
Consulting or Advisory Role - Boehringer Ingelheim; Ipsen; Janssen Oncology; Jazz Pharmaceuticals; Loxo/Lilly; Revolution Medicines
Speakers' Bureau - Ipsen; Jazz Pharmaceuticals
Research Funding - Amal Therapeutics (Inst); Arcus Biosciences (Inst); Loxo/Lilly (Inst); Merck (Inst); Novartis (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst)
Expert Testimony - Merck
 
Ying Yuan
No Relationships to Disclose
 
Victor Moreno
Employment - START
Consulting or Advisory Role - Abbvie; Affimed Therapeutics; AstraZeneca; Basilea; Bayer; BMS; Ellipses Pharma; Janssen Oncology; Merck; Roche
Speakers' Bureau - Bayer; Pierre Fabre
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); ADC Therapeutics (Inst); Amgen (Inst); Ascendis Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioinvent (Inst); Biomea Fusion (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Crescendo Bioscience (Inst); Cullinan Oncology (Inst); E-therapeutics (Inst); Eisai (Inst); F-Star Biotechnology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Grey Wolf Therapeutics (Inst); hemavant (Inst); HiFiBiO Therapeutics (Inst); Janssen (Inst); Kinnate Biopharma (Inst); Menarini (Inst); Merck (Inst); MonTa Biosciences (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Revolution Medicines (Inst); RigonTEC (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst)
Expert Testimony - Medscape/Bayer; Nanobiotix
Travel, Accommodations, Expenses - Sanofi/Regeneron
Other Relationship - BMS
 
Filippo Pietrantonio
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi-Sankyo; Incyte; Ipsen; Johnson&Johnson; Merck Serono; MSD Oncology; Pierre Fabre; Rottapharm Biotech; Seagen; SERVIER; Takeda
Consulting or Advisory Role - Agenus; Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BMS; Daiichi-Sankyo; Gilead Sciences; GlaxoSmithKline; Incyte; Jazz Pharmaceuticals,; Johnson & Johnson/Janssen; Merck Serono; MSD Oncology; Pfizer; Pierre Fabre; Revolution Medicines; Rottapharm Biotech; SERVIER; Takeda
Research Funding - Agenus (Inst); Amgen (Inst); Astrazeneca (Inst); BeOne (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Johnson & Johnson/Janssen (Inst); Lilly (Inst); Rottapharm Biotech (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Johnson & Johnson/Janssen; Merck Serono; Pierre Fabre; Takeda Science Foundation
 
Eric Chen
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Eisai; GlaxoSmithKline; Incyte; Merck; Roche; Takeda
Research Funding - 1Globe Health Institute (Inst); AstraZeneca/MedImmune (Inst); BNT (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Mirati Therapeutics (Inst); Nouscom (Inst); Ono Pharmaceutical (Inst); Pfizer; Repare Therapeutics (Inst); Roche Canada (Inst)
 
Kanwal Raghav
Honoraria - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Consulting or Advisory Role - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Research Funding - Abbvie (Inst); Bayer (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Guardant Health (Inst); HiberCell (Inst); Innovent Biologics (Inst); Janssen (Inst); Merck Serono (Inst); Roche/Genentech (Inst); UCB (Inst); Xencor (Inst)
 
Sanjib Chowdhury
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
 
Xuesong Lu
Employment - Johnson & Johnson/Janssen
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
 
Rianka Bhattacharya
Employment - Johnson & Johnson/Janssen
 
Praveen Barala
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Cecilia Monge
No Relationships to Disclose
 
Seema Sethi
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Sreenivasa Chandana
Leadership - The Cancer & Hematology Centers
Consulting or Advisory Role - AstraZeneca; IPSEN; Novocure
Speakers' Bureau - Natera
Research Funding - Abbvie (Inst); Adcentrx Therapeutics (Inst); Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); BioNTech SE (Inst); BMS (Inst); Cardiff Oncology (Inst); Chugai Pharma (Inst); Corcept Therapeutics (Inst); Dicephera Pharmaceuticals, Inc. (Inst); Elevation Oncology (Inst); Exact Sciences (Inst); Exelixis (Inst); Genentech/Roche (Inst); Halda Therapeutics (Inst); IDEAYA Biosciences (Inst); IDEAYA Biosciences (Inst); IgM Biosciences (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Johnson & Johnson/Janssen (Inst); Medlink (Inst); Merck (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Novocure (Inst); Pfizer (Inst); Qualigen Therapeutics (Inst); Rondo Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Zymeworks (Inst)